245 related articles for article (PubMed ID: 33465670)
41. A monofunctional platinum(II)-based anticancer agent from a salicylanilide derivative: Synthesis, antiproliferative activity, and transcription inhibition.
Wang B; Wang Z; Ai F; Tang WK; Zhu G
J Inorg Biochem; 2015 Jan; 142():118-25. PubMed ID: 25450026
[TBL] [Abstract][Full Text] [Related]
42. Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer.
Zhang Q; Zhou Y; Feng X; Gao Y; Huang C; Yao X
Biomed Pharmacother; 2022 Sep; 153():113426. PubMed ID: 36017794
[TBL] [Abstract][Full Text] [Related]
43. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.
Hua Y; Zhu Y; Zhang J; Zhu Z; Ning Z; Chen H; Liu L; Chen Z; Meng Z
Cell Physiol Biochem; 2018; 51(5):2148-2159. PubMed ID: 30522111
[TBL] [Abstract][Full Text] [Related]
44. Radical-induced DNA damage by cytotoxic square-planar copper(II) complexes incorporating o-phthalate and 1,10-phenanthroline or 2,2'-dipyridyl.
Kellett A; Howe O; O'Connor M; McCann M; Creaven BS; McClean S; Foltyn-Arfa Kia A; Casey A; Devereux M
Free Radic Biol Med; 2012 Aug; 53(3):564-76. PubMed ID: 22659117
[TBL] [Abstract][Full Text] [Related]
45. A Multi-action and Multi-target Ru
Karges J; Yempala T; Tharaud M; Gibson D; Gasser G
Angew Chem Int Ed Engl; 2020 Apr; 59(18):7069-7075. PubMed ID: 32017379
[TBL] [Abstract][Full Text] [Related]
46. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer.
Wang X; Zhang H; Yang H; Bai M; Ning T; Deng T; Liu R; Fan Q; Zhu K; Li J; Zhan Y; Ying G; Ba Y
Mol Oncol; 2020 Mar; 14(3):539-555. PubMed ID: 31901148
[TBL] [Abstract][Full Text] [Related]
47. Anticancer activity of new imidazole derivative of 1R,2R-diaminocyclohexane palladium and platinum complexes as DNA fluorescent probes.
Hadian Rasanani S; Eslami Moghadam M; Soleimani E; Divsalar A; Ajloo D; Tarlani A; Amiri M
J Biomol Struct Dyn; 2018 Sep; 36(12):3058-3076. PubMed ID: 29027501
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
49. Revisiting [PtCl₂(cis-1,4-DACH)]: an underestimated antitumor drug with potential application to the treatment of oxaliplatin-refractory colorectal cancer.
Margiotta N; Marzano C; Gandin V; Osella D; Ravera M; Gabano E; Platts JA; Petruzzella E; Hoeschele JD; Natile G
J Med Chem; 2012 Aug; 55(16):7182-92. PubMed ID: 22788918
[TBL] [Abstract][Full Text] [Related]
50. Novel hyaluronic acid oligosaccharide-loaded and CD44v6-targeting oxaliplatin nanoparticles for the treatment of colorectal cancer.
Du W; Yang X; He S; Wang J; Guo Y; Kou B; Jiang Y; Bian P; Li B; Yin L
Drug Deliv; 2021 Dec; 28(1):920-929. PubMed ID: 33974471
[TBL] [Abstract][Full Text] [Related]
51. Cinnamaldehyde enhances apoptotic effect of oxaliplatin and reverses epithelial-mesenchymal transition and stemnness in hypoxic colorectal cancer cells.
Wu CE; Zhuang YW; Zhou JY; Liu SL; Wang RP; Shu P
Exp Cell Res; 2019 Oct; 383(1):111500. PubMed ID: 31306656
[TBL] [Abstract][Full Text] [Related]
52. Lupeol alters ER stress-signaling pathway by downregulating ABCG2 expression to induce Oxaliplatin-resistant LoVo colorectal cancer cell apoptosis.
Chen MC; Hsu HH; Chu YY; Cheng SF; Shen CY; Lin YJ; Chen RJ; Viswanadha VP; Lin YM; Huang CY
Environ Toxicol; 2018 May; 33(5):587-593. PubMed ID: 29436100
[TBL] [Abstract][Full Text] [Related]
53. A monofunctional platinum complex coordinated to a rhodium metalloinsertor selectively binds mismatched DNA in the minor groove.
Weidmann AG; Barton JK
Inorg Chem; 2015 Oct; 54(19):9626-36. PubMed ID: 26397309
[TBL] [Abstract][Full Text] [Related]
54. Design, modeling, synthesis and biological activity evaluation of camptothecin-linked platinum anticancer agents.
Cincinelli R; Musso L; Dallavalle S; Artali R; Tinelli S; Colangelo D; Zunino F; De Cesare M; Beretta GL; Zaffaroni N
Eur J Med Chem; 2013 May; 63():387-400. PubMed ID: 23517728
[TBL] [Abstract][Full Text] [Related]
55. Kruppel-like factor 5 enhances proliferation, lipid droplet formation and oxaliplatin resistance in colorectal cancer by promoting fatty acid binding protein 6 transcription.
Zuo Q; Xu Q; Li Z; Luo D; Peng H; Duan Z
Anticancer Drugs; 2023 Nov; 34(10):1171-1182. PubMed ID: 37067981
[TBL] [Abstract][Full Text] [Related]
56. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
Wu YZ; Lin HY; Zhang Y; Chen WF
J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
[TBL] [Abstract][Full Text] [Related]
57. Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells.
Zhang Z; Shen C; Zhou F; Zhang Y
Drug Dev Res; 2023 May; 84(3):542-555. PubMed ID: 36779379
[TBL] [Abstract][Full Text] [Related]
58. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
[TBL] [Abstract][Full Text] [Related]
59. Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells.
Wang M; Xiang Y; Wang R; Zhang L; Zhang H; Chen H; Luan X; Chen L
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431875
[TBL] [Abstract][Full Text] [Related]
60. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
Lu WQ; Hu YY; Lin XP; Fan W
Oncotarget; 2017 Jul; 8(27):44171-44185. PubMed ID: 28498807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
